Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Sofie Demasure, Isabel Spriet, Philip R. Debruyne, Annouschka Laenen, Wim Wynendaele, Marcella Baldewijns, Herlinde Dumez, Paul M. Clement, Hans Wildiers, Patrick Schöffski, Eduard Roussel, Lisa Kinget, Maarten Albersen & Benoit Beuselinck. (2022) Overall survival improvement in patients with metastatic clear-cell renal cell carcinoma between 2000 and 2020: a retrospective cohort study. Acta Oncologica 61:1, pages 22-29.
Read now
Read now
Börje Ljungberg, Pernilla Sundqvist, Per Lindblad, Anders Kjellman, Andreas Thorstenson, Mikael Hellström, Britt-Inger Kröger Dahlin, Marcus Thomasson, Ulrika Harmenberg & Sven Lundstam. (2020) Survival advantage of upfront cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma compared with systemic and palliative treatments in a real-world setting. Scandinavian Journal of Urology 54:6, pages 487-492.
Read now
Read now
Josefine Redig, Johan Dalén, Ulrika Harmenberg, Magnus Lindskog, Börje Ljungberg, Sven Lundstam, Rickard Sandin, Thomas Wahlgren, Örjan Åkerborg & Maria Jakobsson. (2019) Real-world cost-effectiveness of targeted therapy in metastatic renal cell carcinoma in Sweden: a population-based retrospective analysis. Cancer Management and Research 11, pages 1289-1297.
Read now
Read now
Sara V. Tornberg, Harri Visapää, Tuomas P. Kilpeläinen, Kimmo Taari, Riikka Järvinen, Kaisa Erkkilä, Harry Nisen & Petrus Järvinen. (2018) Surgery for metastases of renal cell carcinoma: outcome of treatments and preliminary assessment of Leuven-Udine prognostic groups in the targeted therapy era. Scandinavian Journal of Urology 52:5-6, pages 419-426.
Read now
Read now
Articles from other publishers (20)
Flora E. Rodger, Priscilla T. Brennan, Rajesh Nair & David J. Holroyd. (2022) The role of hepatic and pancreatic metastatectomy in the management of metastatic renal cell carcinoma: A systematic review. Surgical Oncology 44, pages 101819.
Crossref
Crossref
Oluwatobi O Onafowokan, Somen Agrawal, Rory G Middleton & Gavin E Bartlett. (2022) Surgical management of renal cancer metastasis in the humerus: novel use of a trabecular metal spacer. BMJ Case Reports 15:2, pages e244313.
Crossref
Crossref
Lauri Laru, Hanna Ronkainen, Pasi Ohtonen & Markku H. Vaarala. (2021) Nephrectomy improves the survival of metastatic renal cell cancer patients with moderate to good performance status—results from a Finnish nation-wide population-based study from 2005 to 2010. World Journal of Surgical Oncology 19:1.
Crossref
Crossref
Naleen Raj Bhandari, Mohamed H. Kamel, Erin E. Kent, Carrie McAdam-Marx, Songthip T. Ounpraseuth, J. Mick Tilford & Nalin Payakachat. (2021) Association of Health-Related Quality of Life with Overall Survival in Older Americans with Kidney Cancer: A Population-Based Cohort Study. Healthcare 9:10, pages 1344.
Crossref
Crossref
Lauri Laru, Hanna Ronkainen & Markku H. Vaarala. (2021) Transition to Targeted Therapies Improved the Prognosis and Increased the Utilization of Medical Treatments among Patients with Synchronous Metastatic Renal Cell Cancer. International Journal of Surgical Oncology 2021, pages 1-7.
Crossref
Crossref
Chun L. Gan, Igor Stukalin, Daniel E. Meyers, Shaan Dudani, Heidi A.I. Grosjean, Samantha Dolter, Benjamin W. Ewanchuk, Siddhartha Goutam, Michael Sander, Connor Wells, Aliyah Pabani, Tina Cheng, Jose Monzon, Don Morris, Naveen S. Basappa, Sumanta K. Pal, Lori A. Wood, Frede Donskov, Toni K. Choueiri & Daniel Y.C. Heng. (2021) Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer 151, pages 115-125.
Crossref
Crossref
Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Hironori Fukuda, Hidekazu Tachibana, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida & Kazunari Tanabe. (2021) Assessing improvements in metastatic renal cell carcinoma systemic treatments from the pre-cytokine to the immune checkpoint inhibitor eras: a retrospective analysis of real-world data. Japanese Journal of Clinical Oncology 51:5, pages 793-801.
Crossref
Crossref
Sabrina H. Rossi, Tobias Klatte, Juliet A. Usher-Smith, Kate Fife, Sarah J. Welsh, Saeed Dabestani, Axel Bex, David Nicol, Paul Nathan, Grant D. Stewart & Edward C.F. Wilson. (2021) A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound. European Urology Focus 7:2, pages 407-419.
Crossref
Crossref
Manish Kohli, Winston Tan, Bérengère Vire, Pierre Liaud, Mélina Blairvacq, Frederic Berthier, Daniel Rouison, George Garnier, Léa Payen, Thierry Cousin, Dominique Joubert & Alexandre Prieur. (2021) Prognostic Value of Plasma hPG80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma. Cancers 13:3, pages 375.
Crossref
Crossref
Hannes Jürgens, Kristiina Ojamaa, Helis Pokker, Kaire Innos & Peeter Padrik. (2020) Changes in therapy and survival of metastatic renal cell carcinoma in Estonia. BMC Cancer 20:1.
Crossref
Crossref
Renzo G. DiNatale, Wanling Xie, Maria F. Becerra, Andrew W. Silagy, Kyrollis Attalla, Alejandro Sanchez, Roy Mano, Julian Marcon, Kyle A. Blum, Nicole E. Benfante, Martin H. Voss, Robert J. Motzer, Jonathan Coleman, Toni K. Choueiri, Ed Reznik, Paul Russo, Daniel Y.C. Heng & A. Ari Hakimi. (2020) The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology 3:1, pages 47-56.
Crossref
Crossref
Martin Bögemann, Aleksandra Zagorska, Divine Akumo, Laila El Hadad & Marc Pignot. (2020) Using Data from a Sickness Fund Claims Database to Assess the Treatment Patterns and Healthcare Resource Utilization among Patients with Metastatic Renal Cell Carcinoma in Germany. Urologia Internationalis 104:11-12, pages 982-993.
Crossref
Crossref
Sumanta Pal, Jun Gong, Shivani K. Mhatre, Shih-Wen Lin, Andy Surinach, Sarika Ogale, Rini Vohra, Herschel Wallen & Daniel George. (2019) Real-world treatment patterns and adverse events in metastatic renal cell carcinoma from a large US claims database. BMC Cancer 19:1.
Crossref
Crossref
Xinan Sheng, Feng Bi, Xiubao Ren, Ying Cheng, Jinwan Wang, Brad Rosbrook, Ming Jiang & Jun Guo. (2019) First-line axitinib versus sorafenib in Asian patients with metastatic renal cell carcinoma: exploratory subgroup analyses of Phase III data. Future Oncology 15:1, pages 53-63.
Crossref
Crossref
Satoshi Tamada, Taro Iguchi, Minoru Kato, Sayaka Yasuda, Takeshi Yamasaki & Tatsuya Nakatani. (2018) Second-line treatment after sunitinib therapy in patients with renal cell carcinoma: a comparison of axitinib and mammalian target of rapamycin inhibitors. Oncotarget 9:97, pages 37017-37025.
Crossref
Crossref
Pawel Chrom, Maciej Kawecki, Rafal Stec, Lubomir Bodnar, Cezary Szczylik & Anna M. Czarnecka. (2018) Biomarkers defining probability of receiving second-line targeted therapy in metastatic renal cell carcinoma. Medical Oncology 35:6.
Crossref
Crossref
R.A. Figlin, B.C. Leibovich, G.D. Stewart & S. Negrier. (2018) Adjuvant therapy in renal cell carcinoma: does higher risk for recurrence improve the chance for success?. Annals of Oncology 29:2, pages 324-331.
Crossref
Crossref
Radek Lakomy, Alexandr Poprach, Zbynek Bortlicek, Bohuslav Melichar, Renata Chloupkova, Rostislav Vyzula, Milada Zemanova, Katerina Kopeckova, Marek Svoboda, Ondrej Slaby, Igor Kiss, Hana Studentova, Jaroslav Juracek, Ondrej Fiala, Jindrich Kopecky, Jindrich Finek, Ladislav Dusek, Karel Hejduk & Tomas Buchler. (2017) Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry. BMC Cancer 17:1.
Crossref
Crossref
Magnus Lindskog, Thomas Wahlgren, Rickard Sandin, Jan Kowalski, Maria Jakobsson, Sven Lundstam, Börje Ljungberg & Ulrika Harmenberg. (2017) Overall survival in Swedish patients with renal cell carcinoma treated in the period 2002 to 2012: Update of the RENCOMP study with subgroup analysis of the synchronous metastatic and elderly populations. Urologic Oncology: Seminars and Original Investigations 35:9, pages 541.e15-541.e22.
Crossref
Crossref
Carsten Nieder, Mohsan A. Syed, Astrid Dalhaug, Adam Pawinski & Jan Norum. (2017) Eligibility for phase 3 clinical trials of systemic therapy in real-world patients with metastatic renal cell cancer managed in a rural region. Medical Oncology 34:9.
Crossref
Crossref